Lazcluze, Rybrevant Approval a ‘Big Deal’ for EGFR-Mutant NSCLC
Before choosing to receive Lazcluze and Rybrevant for EGFR-mutant NSCLC, it's important to consider the pros and cons.Patients with EGFR-mutant ...
Tag: non-small cell lung cancer
6 FDA Cancer Approvals from August 2024
CURE® took a look at six recent FDA approvals in the solid and blood cancer space. During the summer of ...
FDA Approves Lazcluze Plus Rybrevant for Lung Cancer Subset
The Food and Drug Administration (FDA) approved Lazcluze (lazertinib) plus Rybrevant (amivantamab-vmj) for the frontline treatment of patients with locally ...
Body Mass Index May Play a Role in Lung Cancer Treatment Decisions
The body mass index of patients with non-small cell lung cancer may affect whether they should receive chemotherapy or immunotherapy.Patients ...
FDA Approves Presurgical, Postsurgical Imfinzi in Some With NSCLC
The effectiveness of the Imfinzi regimen was evaluated in the phase 3 AEGEAN trial. The Food and Drug Administration (FDA) ...
Polypharmacy May Shorten Survival in Lung Cancer
Survival outcomes are affected for certain older patients with NSCLC who take five or more oral or inhaled medications. Older ...
Olomorasib, Keytruda Combo Is Safe for Lung Cancer Subset
The novel drug, olomorasib, when given with Keytruda (pembrolizumab), was safe and effective in treating KRAS G12C-mutant non-small cell lung ...
ctDNA-Guided Treatment De-escalation Feasible in Advanced NSCLC
Taking a break from TKI treatment may help with mild to moderate side effects, including rash, nail infection or irregular ...
Cancer Vaccine for NSCLC and Melanoma Could Be Paradigm-Changing
The phase 1 study evaluating this cancer vaccine is expected to be completed in June 2025. Some patients with skin ...
Tecentriq Plus Chemoradiation May Be Safe, Effective in Unresectable Stage 3 NSCLC
The disease control rate for patients with surgically unremovable NSCLC was 74.2% after 12 weeks of receiving neoadjuvant Tecentriq. Tecentriq ...
Liquid Biopsy May Be Helpful for Treatment Decisions in ROS1-Positive NSCLC
Genomic testing via liquid biopsies may be beneficial for patients with non-small cell lung cancer who have not previously received ...
Rybrevant Combo Improves Survival in EGFR-Mutated, Advanced NSCLC
Findings from the MARIPOSA trial showed that Rybrevant plus Leclaza outperformed Tagrisso for certain patients with lung cancer.Frontline treatment with ...